27.09.2013 • News

AkzoNobel: Phasing of Restructuring Charges between Q3 and Q4 2013

At the announcement of the Q2 results in July, AkzoNobel indicated that it had identified further efficiency and cost saving measures that would require €120 million of restructuring charges in the second half of 2013.

In addition to the previously announced Performance Improvement Program costs this made a total of €256 million of restructuring charges that were expected to be incurred in the second half of 2013. It is now expected that the majority of these costs will be booked in the fourth quarter with over 20 % to be booked in the third quarter. As previously indicated, the full year 2013 operating income is unlikely to exceed the €908 million of 2012.

Keith Nichols, CFO of AkzoNobel, commented: "The economic environment continues to be challenging but the restructuring program remains on track and the additional initiatives are progressing well. This announcement only refers to the timing of the realization of the costs in the accounts." 

 

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.